The 4th edition of the Hanson Wade Bacteriophage Therapy Summit will be held as a Virtual summit from Monday 14th February till Wednesday 16th February 2022.
What is the 4th Bacteriophage Therapy Summit and Why attend?
The increasing regulatory flexibility for the use of phage-based applications has resulted in the field of phage doubling down on critical questions. These are currently limiting the rapid advancement of phage technologies, particularly the commercial development to reach markets that are beyond compassionate use.
The 4th edition of the Bacteriophage Therapy Summit returns a global industry forum of phage developers that prioritize human health and disease to capitalize on the rapidly evolving antimicrobial landscape. For 3 days, over 100 other phage developers from across the globe from a diversity of fields will gather to gain comprehensive and actionable insights into phage commercialization. Discussions on a range of topics from; developing a regulatory landscape, the up-scaling of manufacturing processes, utilizing genomic data, and clinical design efficacy limiting the widespread commercialization and adoption of phage therapy.
Who will be at the 4th Bacteriophage Therapy Summit?
Over 35 speakers and more than 100 phage developers will be attending.
The summit will bring together individuals in positions and occupations of; Presidents, VPs, Scientists, Investigators, C-Level, Professors, and Associate Professors. Those who work in a diversity of fields such as; drug development, research, NFP, academia, service providers, and consumer brands.
Agenda for the 4th Bacteriophage Therapy Summit 2022
Monday 14th February 2022
Identifying & Understanding Commercial Opportunity for Phage-Application Beyond Human Health
Natasha Klaponski Lab Manager at Cytophage – Developing New Ways to Catch & Kill the COVID-19 Virus
Mathias Middelboe Professor Marine Biology at University of Copenhagen – Use of Phages for Pathogen Control in Aquaculture
Carrie Furr Co-founder & CEO at Bacteriophage & Drug Development Consultants – Non-Traditional Uses of Phage & Phage-Based Products
Steven Theriault CEO & Chief Scientific Officer at Cytophage – Benefits of Using Bacteriophages in a Large Scale Agricultural Setting
Viviana Clavijo CEO at Sciphage – Incentives of Developing Phage Cocktails for Animal Health
Harnessing the Potential of Modified Phages & Phage Lysins
Lorenzo Corsini Co-founder & CEO at Phagomed – PM-477 – A Potent Synthetic Lysin against Bacterial Vaginosis Active on Antibiotic-Resistant Bacteria & Biofilm
Chandrabali Ghose Founder & CEO at Bioharmony Therapeutics – How Phage Lysins are Used to Treat Acinetobacter Baumannii Causing Respiratory Infections
Vincent Fischetti Professor & Head of Lab at The Rockefeller University – Developing Phage Lysins Against Gram-Negative Pathogens
Hannah Tuson Director of Discovery at Locus Biosciences – Applying Synthetic Biology to Bacteriophage Cocktails
Heather Fairhead CEO at Phico Therapeutics – SASPject Engineered Phage Technology for Controlling Multidrug-Resistant Bacteria
Tuesday 15th February 2022
Cara Fiore Microbiologist at the FDA, Office of Vaccines Research & Review – Discussing the FDA Scientific & Regulatory Considerations for Bacteriophage Therapies
Edward Burd Senior Vice President Regulatory Affairs at BiomX – Developing Phage-Based Therapeutics for Unmet Medical Needs: The BiomX Experience
Valeria Gigante Team Lead – One Health Research Priority – Setting & Synergy at WHO – WHO Perspective on Phage Therapies
Tobi Nagel Founder of Phages for Global Health – Phage Banks as Essential Tools for Rapidly and Cost-Effectively Addressing the Antimicrobial Resistance Crisis in the Developing World
Ursela P. Guce Bigol Supervising Science Research Specialist at the Department of Science and Technology at the Industrial Technology Development Institute – Bacteriophages from Hospital Wastewater Against Clinical Bacterial Isolates in the Philippines
Minmin Yen Co-founder & CEO at PhagePro – Phages for All: How to Build an Infrastructure for Phage Therapy in Resource-Limited Settings
Katrine Whiteson Co-director of the Department of Molecular Biology & Biochemistry UCI Microbiome Center – Phage Cocktails More Effectively Constrain Enterococcus Growth
Ronen Hazan Associate Professor & Principal Investigator at the Institute of Biomedical & Oral Research (IBOR) of the Hebrew University – Clinical Phage Microbiology: The Art of Matching
Rebekah Dedrick Research Associate at University of Pittsburgh – Antibody-Mediated Neutralization of Phages for Treatment of a Pulmonary Infection
Saima Aslam Associate Professor at the Division of Infectious Diseases & Global Public Health at iPATH, and Ran Nir Paz Associate Professor & Senior Physician at Hadassah Hebrew University Hospital – Single Center or Single Phage Preparations Experience We Can Learn from eIND Cases on Efficacy
Ameneh Khatami Senior Lecturer and Clinical Academic at University of Sydney & Sydney Children’s Hospitals Network – Therapeutic Phage Monitoring of the Human Host Immune Response
Wednesday 16th February 2022
Danish Malik Reader Industrial Biology at Loughborough University – Quality-By-Design Led Approaches for Manufacturing & Formulation of Phage Therapeutics
Natalie Ma Head of Business Development at Felix Biotechnology – Phages for Faces: Chemical-Free Solutions for the Cosmetics Industry
Mikael Skurnik Professor of Bacteriology at University of Helsinki – Deep Dive into the Characteristics of Phages to Exploit Their Host-Toxic Properties
Melissa Haines NIHR Academic Clinician in Infectious Diseases & Medical Microbiology University Hospitals of Leicester NHS Trust at University of Leicester – Streamlining Microbiology Testing for the Treatment of Antibiotic-Resistant Urinary Tract Infections
Hesham Abdelbary Orthopedic Surgeon at Ottawa Hospital – Can Phages Improve the Management of Prosthetic Joint Infections?
Sabrina Green Director of Research & Development at Baylor – Development of Cocktails for Personalized Therapeutic Use
Zemphira Alavidze Medical Microbiologist at Phage Therapy Center – Can the Compassionate Use of Bacteriophages Ultimately Become Accessible Commercially?
Gina Suh Assistant Professor at Mayo Clinic – Phage Therapy in Implantable Devices: The Mayo Clinic Experience
Iddo Weiner Director & Head of Software at BiomX – Predicting a Phage’s Host-Range from Genomic Data
Chris Lis Co-founder & Chief Technical Officer at Uniphage – Building a Universal Phage Selection Platform by Applying Recent NLP Breakthroughs to Genomic Data of Phages & Bacteria
Bob Blasdel Research Director at Vesale Pharma – Requirements for an In-Vitro Diagnostic to Determine the Phage a Patient Needs on a Routine Basis
View past events by Hanson Wade